SEC Form 4 · accession 0001209191-17-051076
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Brett Primiano
Officer — SVP, OPS, BUS DEV, GC & SEC
Period of report
Jun 26, 2017
Accepted (ET)
Sep 1, 2017 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 26, 2017 | S | 805 | $10.0261 | D | 14,881 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Represents the weighted average sale price. These shares were sold in transactions at $10.00 and $10.07. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price.
- F3Amount also reflects the number of shares sold by the reporting person as previously reported on the Form 4 filed on August 30, 2017 (the "Previous Form 4") as well as the acquisition of 2,062 shares under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, which was previously disclosed on the Previous Form 4.